Every single future medical student who will study at the New York University School of Medicine, in perpetuity, will have their tuition costs fully covered; HHS has approved New Jersey’s waiver request to create a reinsurance program that would help lower insurance premiums for everyone in the state; an analysis highlights how marketing documents from the mid-1990s downplayed addiction to opioids.
Every single future medical student who will study at the New York University (NYU) School of Medicine, in perpetuity, will have their tuition costs fully covered. The New York Times reported that the school cited the “overwhelming” debt medical school graduates face, which causes students to seek careers in higher-paying specialties. The hope is that if students have their medical tuition paid for, it can help alleviate the physician shortage. NYU has currently raised more than $450 million of the $600 million it said it will need to finance the tuition plan.
HHS has approved New Jersey’s waiver request to create a reinsurance program that would help lower insurance premiums for everyone in the state. The waiver allows the state to reimburse insurers for covering high-cost patients, according to the approval. Other states have implemented reinsurance programs with great success, resulting in far lower premium increases than what other states have reported. New Jersey’s Department of Banking and Insurance expects that the reinsurance program will reduce premium rates by approximately 15% compared with what they would be without the program.
A new analysis from Kaiser Health News outlined how Purdue Pharma’s marketing documents for OxyContin in the mid-1990s downplayed addiction. The documents may be a “smoking gun,” according to one expert, in the thousands of pending lawsuits that allege drug makers engaged in deceptive marketing that fueled the current opioid epidemic. Meanwhile, President Donald Trump wants the federal government to get involved. He is asking Attorney General Jeff Sessions to file lawsuits against some companies that supply and manufacture the powerful painkillers.
Health Equity and Access Weekly Roundup: December 9, 2023
December 9th 2023The Center on Health Equity and Access provides information on the latest news, research discoveries, and initiatives dedicated to addressing healthcare disparities and improving overall access to high-quality care.
Read More
New TROPiCS-02 Data Back Sacituzumab Govitecan for Older Patients With Breast Cancer
December 9th 2023This phase 3 study investigated sacituzumab govitecan, a Trop-2–directed antibody-drug conjugate, vs treatment of physician’s choice in pretreated patients who have endocrine-resistant hormone receptor–positive/HER2-negative breast cancer, the most common form of breast cancer.
Read More
California Aims for Equity by Redefining Cancer Care
December 8th 2023Authors highlight key aspects of the California Cancer Care Equity Act, including its focus on Medi-Cal beneficiaries, the requirement for managed care plans to contract with specialized cancer centers, and the definition of complex cancers.
Read More